NCT02842541View on ClinicalTrials.gov

Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

February 28, 2018

Conditions
Diabetic Macular Edema
Interventions
DRUG

EBI-031

Sponsors
All Listed Sponsors
lead

Eleven Biotherapeutics

INDUSTRY